Semler Scientific, Inc.

Founded in 2007 and based in California, US, Semler Scientific, Inc. is a healthcare technology company focused on digital health solutions for chronic disease detection, particularly peripheral arterial disease (PAD). Their leading product, QuantaFlo, enhances diagnostic efficiency for healthcare professionals. The company specializes in digital health technologies for early disease detection.

The leadership team includes CEO Doug Murphy-Chutorian and co-founders Herbert Semler and Johnny Bemma. Semler Scientific, Inc. specializes in digital health technologies aimed at early detection of chronic diseases, focusing on peripheral arterial disease (PAD). Their flagship product, QuantaFlo, is designed for rapid, accurate assessment of blood flow, providing critical data for healthcare professionals.

QuantaFlo utilizes advanced algorithms and non-invasive technology to effectively identify PAD, serving hospitals, outpatient clinics, and healthcare providers across the US and select international markets. Semler’s innovations are aimed at enhancing patient outcomes and streamlining the chronic disease management process. In the most recent fiscal year 2024, Semler Scientific reported a revenue of USD 56. 29 mn and an EBITDA of USD 21.

51 mn. Their business model combines direct sales and partnerships for market entry, generating revenue primarily through the sale of QuantaFlo devices and ongoing support services for healthcare clients. Semler Scientific aims to expand its product line and geographic reach. Upcoming products are currently under development, with specific release dates to be announced in the future.

The company plans to enter new markets, targeting expansion in selected international regions by 2025. Recent funding from their Initial Public Offering will support these initiatives, enhancing their capacity to meet the evolving needs of the healthcare sector.